1. Home
  2. ALT vs AVIR Comparison

ALT vs AVIR Comparison

Compare ALT & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • AVIR
  • Stock Information
  • Founded
  • ALT 1997
  • AVIR 2012
  • Country
  • ALT United States
  • AVIR United States
  • Employees
  • ALT N/A
  • AVIR N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • AVIR Medicinal Chemicals and Botanical Products
  • Sector
  • ALT Health Care
  • AVIR Health Care
  • Exchange
  • ALT Nasdaq
  • AVIR Nasdaq
  • Market Cap
  • ALT 333.6M
  • AVIR 290.4M
  • IPO Year
  • ALT N/A
  • AVIR 2020
  • Fundamental
  • Price
  • ALT $3.93
  • AVIR $3.10
  • Analyst Decision
  • ALT Strong Buy
  • AVIR Hold
  • Analyst Count
  • ALT 6
  • AVIR 1
  • Target Price
  • ALT $17.40
  • AVIR $6.00
  • AVG Volume (30 Days)
  • ALT 3.0M
  • AVIR 389.5K
  • Earning Date
  • ALT 11-11-2025
  • AVIR 11-06-2025
  • Dividend Yield
  • ALT N/A
  • AVIR N/A
  • EPS Growth
  • ALT N/A
  • AVIR N/A
  • EPS
  • ALT N/A
  • AVIR N/A
  • Revenue
  • ALT $20,000.00
  • AVIR N/A
  • Revenue This Year
  • ALT N/A
  • AVIR N/A
  • Revenue Next Year
  • ALT N/A
  • AVIR N/A
  • P/E Ratio
  • ALT N/A
  • AVIR N/A
  • Revenue Growth
  • ALT N/A
  • AVIR N/A
  • 52 Week Low
  • ALT $2.90
  • AVIR $2.46
  • 52 Week High
  • ALT $11.16
  • AVIR $4.02
  • Technical
  • Relative Strength Index (RSI)
  • ALT 52.80
  • AVIR 43.40
  • Support Level
  • ALT $3.85
  • AVIR $2.78
  • Resistance Level
  • ALT $4.06
  • AVIR $3.06
  • Average True Range (ATR)
  • ALT 0.20
  • AVIR 0.10
  • MACD
  • ALT 0.02
  • AVIR 0.02
  • Stochastic Oscillator
  • ALT 57.35
  • AVIR 72.73

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About AVIR Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Share on Social Networks: